Updates are available Correction dated 2024-11-13
Click to view Correction: https://doi.org/10.1007/s00415-024-12721-6
-
Authors
Hébert, Harry L.
Veluchamy, Abirami
Baskozos, Georgios
Fardo, Francesca
Van Ryckeghem, Dimitri
Pearson, Ewan R.
Colvin, Lesley A.
Crombez, Geert
Bennett, David L. H.
Meng, Weihua
Palmer, Colin N. A.
Smith, Blair H. http://orcid.org/0000-0002-5362-9430
-
Funding
Funding for this research was provided by:
Chief Scientist Office, Scottish Government Health and Social Care Directorate (CZD/16/6)
Scottish Funding Council (HR03006)
Wellcome Trust (072960/Z/03/Z, 084726/Z/08/Z, 084727/Z/08/Z, 085475/Z/08/Z, 085475/B/08/Z)
Horizon 2020 Framework Programme (633491)
- License Information
-
More Information
Article History
Received: 28 April 2022
Revised: 3 November 2022
Accepted: 4 November 2022
First Online: 10 November 2022
Change Date: 13 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-024-12721-6
Declarations
:
: DLHB has acted as a consultant on behalf of Oxford Innovation for Amgen, Bristows, LatigoBio, GSK, Ionis, Lilly, Olipass, Orion, Regeneron and Theranexus over the last 2 years. He has received research funding from Lilly. He has received an industrial partnership grant from the BBSRC and AstraZeneca. All other authors declare no conflict of interest.
: This study adheres to the Declaration of Helsinki Principles and was approved by Yorkshire and The Humber–South Yorkshire Research Ethics Committee (15/YH/0285). Ethical approval was already in place for the pre-existing GoDARTS (053/04) and GS (05/S1401/89) cohorts. Participants provided informed consent to participate in GoDARTS or GS and to be contacted again for future studies (including DOLORisk Dundee). Furthermore, participants provided informed consent to be contacted about the DOLORisk Dundee follow-up survey. The return of a completed questionnaire was taken as consent to participate in DOLORisk Dundee.
